Chemokine-enhanced DNA vaccination in cancer immunotherapy

OncoImmunology

Volumn 2, Issue 10, 2013, Pages

  Igoucheva, Olga ^a   Jonas, Rebecca ^a   Alexeev, Vitali ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chemokines; Dna vaccine; Intradermal vaccination; Intratumoral vaccination; Leukocyte recruitment; Therapeutic vaccine

Indexed keywords

CHEMOKINE; DNA VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CELL EXPANSION; CELL TRANSPORT; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA IMMUNIZATION; DRUG ADMINISTRATION ROUTE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR MECHANICS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

EID: 84890280167     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26092     Document Type: Article

References (10)

1. Alexeev V, Pidich A, Kemp D, Igoucheva O. Recombinant DNA technology in emerging modalities for melanoma immunotherapy. In: Huynh G (ed) Melanoma: From early detection to treatment. Intech: Rijeka, Croatia, 2013, pp 175-194
2. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov 2011; 10:411-2; PMID:21629286; http://dx.doi.org/10.1038/nrd3463
3. Alexeev V, Mucci T, Igoucheva O. Immunotherapeutic strategies for the treatment of malignant melanoma. G Ital Dermatol Venereol 2008; 143:139-49; PMID:18833040
4. Novak L, Igoucheva O, Cho S, Alexeev V. Characterization of the CCL21-mediated melanomaspecific immune responses and in situ melanoma eradication. Mol Cancer Ther 2007; 6:1755-64; PMID:17575105; http://dx.doi.org/10.1158/1535-7163.MCT-06-0709
5. Igoucheva O, Grazzini M, Pidich A, Kemp DM, Larijani M, Farber M, Lorton J, Rodeck U, Alexeev V. Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine. Gene Ther 2013; 20:939-48; PMID:23552473; http://dx.doi.org/10.1038/gt.2013.17
6. Wu A, Zeng Q, Kang TH, Peng S, Roosinovich E, Pai SI, Hung CF. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther 2011; 18:304-12; PMID:20981112; http://dx.doi.org/10.1038/gt.2010.151
7. Park JY, Jin DH, Lee CM, Jang MJ, Lee SY, Shin HS, Chung YH, Kim KY, Kim SS, Lee WB, et al. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells. J Immunother 2010; 33:510- 22; PMID:20463596; http://dx.doi.org/10.1097/CJI.0b013e3181d75cef
8. Flanagan K, Moroziewicz D, Kwak H, Hörig H, Kaufman HL. The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell Immunol 2004; 231:75-84; PMID:15919372; http://dx.doi. org/10.1016/j.cellimm.2004.12.006
9. Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Kusser K, Randall TD. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc Natl Acad Sci USA 2007; 104:10577-82; PMID:17563386; http://dx.doi.org/10.1073/pnas.0700591104
10. McDonald KG, McDonough JS, Wang C, Kucharzik T, Williams IR, Newberry RD. CC chemokine receptor 6 expression by B lymphocytes is essential for the development of isolated lymphoid follicles. Am J Pathol 2007; 170:1229-40; PMID:17392163; http:// dx.doi.org/10.2353/ajpath.2007.060817